Resumo

MANZUR, Fernando  e  MONERIZ, Carlos. Canakinumab: a promising monoclonal antibody in the treatment of cardiovascular diseases. Rev. Colomb. Cardiol. [online]. 2013, vol.20, n.1, pp.33-39. ISSN 0120-5633.

Canakinumab is a totally human monoclonal antibody anti-IL-1β developed by Novartis, whose mode of action is based on the neutralization of IL-1β signaling, which leads to suppression of inflammation in patients with autoimmune disorders. The IL-1β acts as a mediator of the peripheral immune response during infection and inflammation. By the antigen-antibody binding, canakinumab inhibits the action of IL1-β avoiding its pro-inflammatory effects. Currently, it is being evaluated as a new possible agent directed against IL-1β, with the goal of reducing the rate of cardiovascular events and new onset diabetes (study CANTOS).

Palavras-chave : cardiovascular risk factors; biomarkers; diagnosis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )